Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
02:00pm, Saturday, 24'th Jan 2026
Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:40am, Thursday, 15'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:25pm, Monday, 12'th Jan 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 09'th Jan 2026
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now?
10:40am, Thursday, 08'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
08:03am, Thursday, 08'th Jan 2026
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
08:03am, Monday, 05'th Jan 2026
CORAL GABLES, Fla. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical co
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?
11:06am, Wednesday, 31'st Dec 2025
Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals (CPRX +0.21%), exercised and immediately sold 10,983 shares of common stock on November 26, 2025, for a total value of approxim
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 30'th Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Contrasting Organogenesis (NASDAQ:ORGO) & Catalyst Pharmaceuticals (NASDAQ:CPRX)
01:14am, Sunday, 28'th Dec 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) and Organogenesis (NASDAQ: ORGO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two co
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:51am, Tuesday, 23'rd Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX
05:32am, Monday, 22'nd Dec 2025
Toth Financial Advisory Corp trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 96.5% in the third quarter, according to its most recent Form 13F filing with the Securi
Insider Selling: Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Sells $621,844.50 in Stock
04:44am, Friday, 19'th Dec 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX - Get Free Report) Director Molly Harper sold 26,746 shares of the firm's stock in a transaction dated Friday, December 12th. The shares were sold at an av
CPRX vs. DSNKY: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 17'th Dec 2025
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Wall Street Analysts See a 42.62% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
10:56am, Wednesday, 17'th Dec 2025
The mean of analysts' price targets for Catalyst (CPRX) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
